Medidata (MDSO), crunches big data for health care companies at the research level. It not only has apps that help organize and study the research starting from the project stage to the clinical trial stage, but it also has an app that allows patient input into the data.  The company has a financial tracking system that lets its clients keep track of who is getting paid and how much, as well as keeping trends and other financial variables in focus.  They are expected to report earnings in late April.  Revenues and earnings have been steadily rising.  

I am adding Medidata to the Medical Profits Portfolio with a buy limit of $39 and a stop loss of $32. In the current environment where money for health care expenses is expected to decrease, MDSO is well positioned.